Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. by Lienhardt, Christian et al.
Lienhardt, C; Fielding, K; Hane, AA; Niang, A; Ndao, CT; Karam,
F; Fletcher, H; Mbow, F; Gomis, JF; Diadhiou, R; Diadhiou, R;
Toupane, M; Dieye, T; Mboup, S (2010) Evaluation of the Prog-
nostic Value of IFN-gamma Release Assay and Tuberculin Skin Test
in Household Contacts of Infectious Tuberculosis Cases in Senegal.
PLoS One, 5 (5). e10508. ISSN 1932-6203
Downloaded from: http://researchonline.lshtm.ac.uk/3701/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
Evaluation of the Prognostic Value of IFN-c Release
Assay and Tuberculin Skin Test in Household Contacts of
Infectious Tuberculosis Cases in Senegal
Christian Lienhardt1*, Katherine Fielding2, Abdoul A. Hane3, Aliou Niang3, Cheikh T. Ndao1, Farba
Karam4, Helen Fletcher5, Fatou Mbow1, Jules-Franc¸ois Gomis1, Roger Diadhiou4, Maxime Toupane4,
Tandakha Dieye4, Souleymane Mboup4
1 Institut de Recherche pour le De´veloppement, Programme Tuberculose, Dakar, Senegal, 2 Infectious Disease Epidemiology Unit, London School of Hygiene & Tropical
Medicine, London, United Kingdom, 3 Service de Pneumologie, Hoˆpital Fann, Dakar, Senegal, 4 Laboratoire de Bacte´riologie–Virologie, Hoˆpital Aristide Le Dantec, Dakar,
Senegal, 5Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), University of Oxford, Churchill Hospital, Oxford, United Kingdom
Abstract
Background: Chemoprophylaxis of contacts of infectious tuberculosis (TB) cases is recommended for TB control, particularly
in endemic countries, but is hampered by the difficulty to diagnose latent TB infection (LTBI), classically assessed through
response to the Tuberculin Skin Test (TST). Interferon-gamma release assays (IGRA) are proposed new tools to diagnose
LTBI, but there are limited data on their ability to predict the development of active TB disease. To address this, we
investigated the response to TST and IGRA in household contacts of infectious TB cases in a TB high-burden country and the
potential correlation with development of TB.
Methodology/Principal Findings: Prospective household contacts study conducted in two health centres in Dakar, Senegal.
A total of 2679 household contacts of 206 newly detected smear and/or culture positive index TB cases aged 18 years or
greater were identified A TST was performed in each contact and an ESAT6/CFP10 ELISPOT assay performed in a random
sample of those. Contacts were followed-up for 24 months. TB was diagnosed in 52 contacts, an incidence rate of 9.27/1000
person-years. In univariable analysis, the presence of positive TST ($10 mm) and ELISPOT (.32 SFC/million PBMC)
responses at baseline were associated with active TB during follow-up: Rate Ratio [RR] = 2.32 (95%CI:1.12–4.84) and RR = 2.09
(95%CI:0.83–5.31), respectively. After adjustment for age, sex and proximity to index case, adjusted RRs were 1.51
(95%CI:0.71–3.19) and 1.98 (95%CI:0.77–5.09), respectively. Restricting analysis to the 40 microbiologically confirmed cases,
the adjusted RR for positive ELISPOT was 3.61 (95%CI:1.03–12.65). The median ELISPOT response in contacts who developed
TB was 5-fold greater than in those who did not develop TB (p = 0.02).
Conclusions/Significance: TST and IGRAs are markers of a contact of the immune system with tubercle bacilli. In a TB
endemic area, a high ELISPOT response may reflect increased bacterial replication that may subsequently be associated with
development of TB disease and may have a prognostic value. Further longitudinal data are needed to assess whether IGRAs
are reliable markers to be used for targeting chemoprophylaxis.
Citation: Lienhardt C, Fielding K, Hane AA, Niang A, Ndao CT, et al. (2010) Evaluation of the Prognostic Value of IFN-c Release Assay and Tuberculin Skin Test in
Household Contacts of Infectious Tuberculosis Cases in Senegal. PLoS ONE 5(5): e10508. doi:10.1371/journal.pone.0010508
Editor: Madhukar Pai, McGill University, Canada
Received February 4, 2010; Accepted March 30, 2010; Published May 6, 2010
Copyright:  2010 Lienhardt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study has been conducted under funding from the European Commission, Framework Programme 5, Project QOL 2001-01613. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lienhardtc@who.int
Introduction
For decades, the diagnosis of Latent Tuberculosis Infection
(LTBI) has relied on the Tuberculin Skin Test (TST), which
measures a delayed-type hypersensitivity response to a purified
protein derivative (PPD) of more than 200 M. tuberculosis antigens
[1]. TST suffers, however, limitations due to cross-reactions with a
wide range of environmental mycobacteria and the BCG vaccine
[2]. The characterisation of immunogenic antigens in the Region
of Difference 1, a genomic region present in the M. tuberculosis
complex but deleted from M. bovis BCG and most environmental
mycobacteria, has allowed the development of highly-specific
immuno-diagnostic tests for TB infection [3]. These tests measure
the release of interferon-c by blood T cells that have been
activated in-vitro by M. tuberculosis specific antigens, mainly ESAT-
6 and CFP10 [4]. Studies have suggested that Interferon-c Release
Assays (IGRAs) using the ESAT-6/CFP-10 antigens were more
specific than the TST for the diagnosis of latent TB infection [5]
and at least as sensitive. Subsequently, IGRAs are increasingly
recommended for the detection of LTBI [6,7]. In addition, based
on the hypothesis that T cell response to TB specific antigens
correlate with bacterial replication, it has been suggested that
IGRAs may help to identify individuals at greatest risk for
development of active TB disease who may therefore benefit from
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preventive therapy [8,9]. There are however limited data on the
prognostic ability of IGRAs to predict the development of active
TB disease. We report here results of a prospective household
contact study carried out in Senegal, in which contacts of active
TB cases were tested at baseline with an in-house ESAT-6/CFP-
10 ELISPOT assay (referred to as ‘‘ELISPOT’’) in the rest of the
article and followed-up for two years to detect occurrence of
tuberculosis.
Methods
Setting
The study was conducted in Dakar, Senegal, from March 2004
to April 2006. The total population in Dakar is 2 million, and the
reported incidence of newly diagnosed sputum smear–positive TB
is 132 cases per 100,000 population per year [10].
Design
Newly detected pulmonary tuberculosis cases aged 18 years or
greater with at least 1 sputum smear positive for acid-fast bacilli
and/or a positive culture, identified in two health centres in Dakar
(Fann Hospital and Pikine Health Centre), who were living at the
same address for more than 3 months and gave informed consent,
were eligible for inclusion in the study. An antero-posterior chest
X-ray was performed in each case, and was read by one of the
clinicians. After counselling, cases were invited to undergo an HIV
test.
The household of each index case was visited by trained field
assistants within a week of their recruitment. We defined
household as the extended family living together in the same
area, eating from the same pot [11]. A written informed consent
was obtained from each household member or child care-taker
prior to enrolment. Demographic information was collected from
all individuals (adults and children) living in the household for
more than 3 months as well as their past disease history, presence
of risk factors for TB and relatedness to the index case. Intensity of
exposure to the index case within the household was estimated
through a purposely defined gradient of exposure evaluating the
physical proximity of the household member to the index case at
night-time: (i) share same room and same bed as the index case; (ii)
shares same room but not same bed; (iii) shares same house but not
same room; (iv) dos not sleep in the same house [11]. In addition,
the amount of time and activities shared with the case during the
day were estimated as: ‘‘eating with the index case (i) daily, (ii) less
than daily, (iii) not eating with the case; as well as’’recreational
activities with the index case (i) daily, (ii) less than daily, (iii) not at
all. Following national guidelines, mothers/guardians of children
#5 years old were advised to go the health centre for a 6-month
prophylaxis with isoniazid, and a special transfer voucher was
delivered to them for this.
Each household member was examined for the presence of a
BCG scar, and screened for signs and symptoms of tuberculosis.
Those in whom TB was diagnosed as a result of the enrolment visit
were excluded from all analyses. Blood samples were obtained for
ELISPOT from 10 randomly selected contacts per household: all
members were listed and their name written on pieces of paper
that were put in an urn. A person was chosen to pull out names of
10 household members who underwent ELISPOT testing. If the
household size was ,10, then all members underwent ELISPOT
testing. All contacts were skin-tested with tuberculin (RT23 2TU,
Staten Serum Institute) on the same day, after blood was drawn.
Trained field workers visited all contacts after 48–72 hours to
measure the skin induration.
Households were visited at 3, 6, 12, 18 and 24 months after
recruitment into the study, in order to identify persons who left the
household (either temporarily or permanently) and detect any
suspect TB case. Household members were educated on the signs
and symptoms of the disease to encourage self-referral to Fann
Hospital in the event of suspected tuberculosis. At each home visit,
household members were queried on symptoms and signs
suggestive of TB (cough .3 weeks, fever, loss of weight, night
sweats, chest pain, haemoptysis). Suspect TB cases were referred to
the same clinician at Fann Hospital for clinical examination and
further investigation, including collection of two sputa for smear
and culture, chest X-ray and gastric lavage. Chest X-rays were
read independently of TST and IGRAs results. In order to
account for the difficulty of diagnosing tuberculosis in adults with
smear negative or extra-pulmonary disease and in children, we set
up a certainty grading system that quantifies the likelihood of
tuberculosis diagnosis, based on several published systems [11].
Cases of tuberculosis were graded as ‘‘possible’’, ‘‘probable’’ or
‘‘definite’’ (see Box S1).
The ESAT-6/CFP-10 IFN-c ELISPOT assay. The assay
was performed on freshly isolated peripheral blood mononuclear
cells (PBMCs), as previously described [12], predominantly using
one pool of 35 15-mer peptides, overlapping by 10 amino-acids
(10 mg/ml) and spanning the length of CFP-10 (18 peptides) and
ESAT-6 (17 peptides) (Mabtecch AB, Sweden). Briefly, 200,000
PBMCs per well were plated directly onto the ELISPOT plate
(MAIP, Millipore) in the presence of the peptides, and incubated
for 18 hours. Phytohaemagglutinin (PHA) (5 mg/ml) (Sigma,
Missouri, USA) as positive control and media as negative
control, were added to duplicate wells. ELISPOT plates were
counted using an AID plate reader (Autoimmun Diagnostika,
Strasburg, Germany).
The in-house EC-ELISPOT assay performed in Senegal is
equivalent to the EC-ELISPOT assay performed in The Gambia
[13]. The technique originated from the same Oxford University
laboratory and a trained laboratory technician from the Gambia
helped to establish the assay in Senegal. Head to head
comparisons of the Gambian and Senegalese assays were
performed and good correlation was found between the two
assays (data not shown).
We set two thresholds for positive response to an antigen pool:
(i) more than 20 spot forming cells (SFC)/106 PBMC after
negative control well SFC subtraction and (ii) more than 32 SFC/
106 PBMC after negative control well SFC subtraction. The cut-
off of 32 SFC/million was selected as it is equivalent to the cut-off
of 8 SFC/well used in previously published EC-ELISPOT studies
conducted in The Gambia [13]. The lower cut-off of 20 SFC/
million is closer to that of the commercial T-SPOT assay and the
original ESAT-6/CFP-10 ELISPOT assay [14]. Assays were
excluded if there were more than 20 spots in the negative control
wells, and the remaining n= 1196 assays were used for analysis.
Assays were considered valid if there were at least 250 SFC/106
PBMC in either PHA or purified protein derivative (PPD) wells.
Amongst the 1196 assays, n = 952 (80%) had a valid PHA/PPD
response and n=244 (20%) assays were considered invalid and
therefore excluded from further analysis.
Analysis
Risk factors for time to TB episode during follow-up were
analysed using Cox proportional hazards regression. The primary
risk factors of interest were TST and ELISPOT responses at
enrolment. Other factors measured at the household or TB index
level were considered potential confounders or effect modifiers.
The period of risk started at the date of household member
Prediction of TB
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enrolment plus 60 days so as to exclude co-prevalent TB cases (ie.
TB cases in household members diagnosed as a result of the
enrolment visit). The period of risk ended at either the 24 month
follow-up visit, the midpoint of the last visit seen (if earlier than
month 24) and the following scheduled visit date, date of death or
date of TB diagnosis (defined as the start date for treatment)
whichever came first. Factors with a P value of,0.10 or those that
changed the hazard ratio for TST or ELISPOT response by
Figure 1. Study Profile.
doi:10.1371/journal.pone.0010508.g001
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greater than 10% were considered for the multivariable analysis.
Age group and gender were considered a priori confounders.
Variables were retained in the model if their inclusion changed the
effect of the TST or ELISPOT response on TB incidence by
greater than 10%. The likelihood ratio test was used to assess
general association between risk factors and outcome. Tests for
departures from linearity and for linear trend were carried out for
the association of ordinal factors with outcome.
Ethical aspects
This study proposal was approved by the Ethics Review
Committee of the European Commission. The full protocol and
informed consent forms were approved by the Ethical Committee
of the National Centre for Scientific Research of the Ministry of
Health, Senegal.
International guidelines recommend that children #5 years
who are contacts of a smear positive TB case and are TST positive
be offered preventive therapy with isoniazid (IPT) at a dose of
5 mg/kg for 6 months. The Senegalese ethics committee
recommended that we follow these guidelines. Subsequently, at
recruitment, parents/guardians of child contacts aged #5 years
were requested to go to the local health clinic to get preventive
therapy and a special referral form was completed and given to
them for this. Unfortunately, the provision of IPT to children was
very irregularly ensured at the public health centres in Senegal at
the time of the study. Since anti-tuberculous treatment in Senegal
can only be provided through the National TB Control
Programme, the study team was unable to provide IPT to all
child contacts recruited in the study.
Results
From March 2004 to April 2006, 244 smear positive index TB
cases were recruited. The households of 206 (84%) of these cases
were included in the study, representing 2762 household
members. The reasons for 38 households of index cases not being
included in the study are summarised in Figure 1. Of the 2762
household members, 13 (0.5%) were diagnosed with TB as a result
of screening at the enrolment visit, and one died with TB within 60
days of recruitment. A further 69 (2.5%) household members had
no follow-up visits, leaving 2679 contact persons from 206
households available for analysis (Figure 1). The median age of
the 206 index cases was 28 years (range 18–71 years), 68% were
male and the median time with cough prior to TB diagnosis was 6
weeks (range 1–52 weeks) (Table 1). All were smear positive and
85% were culture positive. The large majority (85%) had at least
one cavity on the chest X-ray.
Of the 2679 household members, 46% were female and the
median age was 20 years (interquartile range [IQR] 10–31 years),
including 390 (14.6%) children aged #5 yrs. The median
household size was 12 persons (IQR: 7–17), and the large majority
of members (86%) had lived in the household for more than 12
months. TST was performed and measured on 2458 individuals,
while ELISPOT response was measured in 952 household
members (n = 186 households) only, due to financial constraints.
Follow-up of household members at the scheduled visits is
summarised in Figure 1. At month 12 and 24, 94% (n= 2527)
and 91% (n= 2425) were present at the follow-up visit,
respectively. The median follow-up was 1.91 years (IQR: 1.83–
2.59) giving a total of 5606.5 person-years [pyrs] of follow-up.
During this time, 52 cases (2%) satisfying the case definition for TB
were diagnosed, giving an incidence rate of 9.27/1000 pyrs (95%
confidence interval [CI]: 7.07–12.17) (Table 2). The 52
secondary cases came from 41 households, with 32 households
having one secondary case, 8 households having two secondary
cases and one household having four secondary cases. The median
age was 25 years (IQR 18.5–32), and 56% were females. The
median time to development of TB was 8.3 months (range 0.4–
28.4 months). The large majority of cases (n = 43, 84%) had
pulmonary TB, while 7 (13%) had extra-pulmonary disease and 2
(4%) had extra-pulmonary disease associated with pulmonary TB.
Forty incident TB cases satisfied the ‘‘definite’’ case definition,
based on microbiology results.
The univariable analysis is presented in Table 3 for all TB
cases (n = 52), and in Table 4 for definite TB cases only (n = 40).
A TST response of 10 mm or more was associated with over a
two-fold increase in the risk of TB (Hazard Ratio [HR]: 2.37,
95%CI: 1.15–4.89). When TST response was categorized into
four levels, there was nearly five-fold increase in risk for those with
a response 15 mm or greater compared with a baseline level of
,5 mm (HR: 4.92, 95%CI: 1.74–13.92). Among household
members in whom ELISPOT was being tested, those who
presented an ELISPOT response $32 SFC/106 PBMC had
more than a two-fold increased risk of developing TB in follow-up
compared with those with a response ,32 SFC/106 PBMC (HR:
1.98, 95%CI: 0.74–5.33). When restricting the analysis to definite
TB cases only (n = 40) (Table 4), the risk of developing TB given a
positive TST response increased slightly. The association with
a positive ELISPOT response appeared, however, stronger, with a
nearly 4-fold increase in hazard of developing TB when response
at baseline was $32 SFC/106 PBMC.
Table 1. Summary of index cases (n = 206).
Variable Coding Summary
Age (years) Median (IQR)
Range
28 (23, 38)
18, 71
Gender1 n (%) Male
Female
n
139
66
(col %)
(67.8)
(32.2)
Culture2 Positive
Negative
106
19
(84.8)
(15.2)
Smear positivity3 Scanty4
1+
2+
3+
8
45
69
78
(4.0)
(22.5)
(34.5)
(39.0)
Cavitation on chest
radiograph5
0
1–2
3–8
27
103
53
(14.7)
(56.3)
(29.0)
Number of zones on chest
radiograph6
0–3
4–5
6
150
41
7
(75.8)
(20.7)
(3.5)
Cough duration7 (weeks) ,3
3–4
5–8
.8
18
71
57
50
(9.2)
(36.2)
(29.1)
(25.2)
HIV status8 Positive
Negative
5
67
(4.3)
(95.7)
1n = 1 missing;
2n = 81 missing;
3degree of positivity not known for n = 6 (all known to be smear positive);
4of n = 8 scanty, n = 1 had a single smear scanty and culture positive, n = 4 have
two scanty smears and n= 3 have three scanty smears;
5n = 23 missing;
6n = 8 missing;
7n = 10 missing;
8n = 134 missing.
IQR = interquartile range; col = column
doi:10.1371/journal.pone.0010508.t001
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The incidence of TB for household contacts aged 5 years or less
was 1.20/1000 pyrs (1 TB episode/834.9 pyrs) and increased with
age (p,0.0001). History of previous episode of TB was also
associated with an increased hazard of TB (p,0.0001). However,
when restricting the analysis to household members with a prior
history of TB, there was no association of time since last episode
on TB incidence (p = 0.40; data not shown), but the numbers of
events in the various time categories were small.
The risk of TB clearly increased with closer proximity of the
household member to the index case at night time (p= 0.002), as
well as with the amount of time and activities shared with the
index TB case at day time, including eating daily with index case
(p = 0.007). Amongst contacts aged .15 years, being a smoker
increased the risk of TB two-fold (HR: 2.15, 95%CI: 1.00–4.60).
There was no effect of BCG vaccination or factors reflecting
infectivity of the index case on the time to TB episode in
household contacts.
After adjustment for age, sex and proximity to index case at
night time, the adjusted hazard ratio [aHR] for developing TB in
two years follow-up when having a TST response of 10 mm or
greater was reduced to 1.55 (95%CI: 0.74–3.24) (Table 5). The
effect was stronger for a TST response greater or equal to 15 mm
when compared to a response less than 5 mm (aHR: 2.56,
95%CI: 0.88–7.41). Household members with an ELISPOT
response of 32 SFC/106 PBMC or greater had nearly a two-fold
increased rate of developing TB in follow-up compared to those
with a response ,32 (aHR: 1.98; 95%CI: 0.77–5.08). When
restricting to definite TB cases only, the adjusted hazard ratio for
active TB in contacts with positive TST response was similar to
the analysis using all TB cases (aHR:1.73, 95%CI: 0.71–4.23),
while it remained high for individuals with an ELISPOT
response $32 SFC/106 PBMC compared to those with a
response ,32 (aHR:3.61, 95%CI: 1.03–12.65, p = 0.02). An
analysis taking into account the potential within household
clustering using a Poisson random effects regression gave very
similar results (data not shown).
Quantitatively, the median ELISPOT response at baseline in
household members who developed TB in follow-up was 250 vs.
50 SFC/106 PBMC in those who did not develop TB (Wilcoxon
rank-sum test, p = 0.02) (Fig. 2). Among household members with
a positive ELISPOT response ($32 SFC/106 PBMC - n= 554),
those with active TB in follow-up had a higher median response
than those without TB (312.5 versus 185 SFC/106 PBMC,
respectively; p= 0.06).
A total of n= 893 household members had data on both TST
and ELISPOT responses (Table 6). Those who had a positive
response to both TST and ELISPOT had higher rate of TB in two
years follow-up (14,74/1000 pyrs), compared to those positive on
either test (11.15/1000 pyrs), although 95%CIs are wide and
overlap. Individuals with both TST and ELISPOT negative
response had a rate of TB of 9.85/1000 pyrs. However,
households where the ELISPOT test was performed (n= 186)
were similar to those where no ELISPOT test was carried out
(n = 20), based on household size (p = 0.57), age (p = 0.57) and sex
(p = 0.20) of the index case.
Discussion
In this prospective study of healthy household contacts of TB
patients in Senegal, we found that the presence of either a positive
TST or a positive EC ELISPOT response at baseline was
associated with a two-fold increased hazard of time to active TB
disease over a two year follow-up period compared to those who
were Mantoux or ELISPOT negative. When adjusting on age, sex
Table 2. Summary of secondary cases in household members (n = 52).
Variable Coding
Overall summary
(n =52)
Summary
age ,16 yrs
(n =6)
Summary
age $16 yrs
(n =46)
Age (years) Median (IQR)
Range
25 (18.5,32)
0, 70
14
0, 15
27
16, 70
n (col %) n (col %) n (col %)
Gender Male
Female
23
29
(44.2)
(55.8)
2
4
(33)
(67)
21
25
(46)
(54)
Smear status Positive 341 (72.3) 42 (80) 303 (71)
Smear positivity
(of those smear positive)
Scanty
1+
2+
3+
1
9
14
10
(2.9)
(26.5)
(41.2)
(29.4)
0
2
0
2
(50)
(50)
1
7
14
8
(3)
(23)
(47)
(27)
Culture Positive 281 (59.6) 32 (60) 253 (60)
Definition of TB Definite
Probable
Possible
40
2
10
(76.9)
(3.8)
(19.2)
4
0
2
(67)
(33)
36
2
8
(78)
(4)
(17)
Type of TB PTB alone
EPTB alone
PTB+EPTB
43
7
2
(83.7)
(13.5)
(3.8)
5
0
1
(83)
(17)
38
7
1
(83)
(15)
(2)
Time to diagnosis
of TB (months) 4
Median (IQR)
Range
8.3 (3.3–11.9)
0.4, 28.4
6.4
1.1–14.8
8.3 (3.5 – 12.3)
0.4 – 28.4
1n = 5 missing,
2n = 1 missing,
3n = 4 missing,
4measured from HH member enrolment +60 days.
IQR = interquartile range; PTB =pulmonary TB; EPTB = extra-pulmonary TB; col = column.
doi:10.1371/journal.pone.0010508.t002
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and proximity to case, all factors independently associated with
development of TB in contacts of TB cases [15], the hazard of
developing TB was 1.5 greater when TST response was .10 mm
and 2.6 greater when TST response was.15 mm. Using the most
stringent threshold, the time to TB episode in subjects with positive
ELISPOT response at baseline remained about two-fold higher
than in those with a negative response. Although not statistically
significant, both estimates of the hazard ratios are comparable and
in the same direction, suggesting that increased exposure to
mycobacterial antigens is associated with increased risk of
development of TB disease within the next two years. Moreover,
there was a quantitative relation between the level of ELISPOT
Table 3. Univariable analysis of time to TB episode; hazard ratios, 95% CI and P-values (nmax = 2679) - All TB cases (n = 52).
Variable Description n (col %)
Rate/
1000 pyrs TB cases/pyrs
Unadjusted HR
(95% CI) P-value
TST response1 (mm) ,10
$ 10
867 (35)
1591 (65)
4.89
11.71
9/1840
39/3332
1
2.37 (1.15–4.89)
0.01
TST response 1 (mm)
,5
5–9
10–14
$ 15
548 (22)
319 (13)
688 (28)
903 (37)
3.31
7.27
4.75
16.49
4/1195
5/645
7/1443
32/1889
1
2.18 (0.59–8.13)
1.40 (0.41–4.79)
4.92 (1.74–13.92)
0.0002
EC response2
(SFC/million PBMC)
,20
$ 20
337 (35)
615 (65)
6.85
13.56
5/730
18/1327
1
1.98 (0.74–5.33)
0.15
EC response2
(SFC/million PBMC)
,32
$ 32
408 (43)
544 (58)
6.86
14.37
6/875
17/1183
1
2.13 (0.84–5.41)
0.09
Gender Male
Female
1420 (53)
1259 (47)
8.75
9.74
23/2630
29/2977
1
1.11 (0.65–1.93)
0.70
Age (years)
#15
16–29
$ 30
1031 (38)
897 (33)
751 (28)
2.71
15.30
11.54
6/2216
28/1830
18/1560
1
5.50 (2.28–13.29)
4.18 (1.66–10.52)
,0.0001
Duration of residence with
index case3 (months)
,6
6–12
.12
199 (7)
173 (6)
2293 (86)
2.47
2.97
10.33
1/404
1/336
50/4840
0.23 (0.03–1.67)
0.27(0.04–1.96)
1
0.05
Eat with index case4
No
Less than daily
Daily
745 (28)
660 (25)
1273 (48)
5.89
5.12
13.28
9/1527
7/1366
36/2711
1
0.87 (0.33–2.35)
2.33 (1.12–4.83)
0.007
Proximity to index
case at night4
Other house
Same house
Same room
Same bed
430 (16)
1764 (66)
213 (8)
271 (10)
7.21
6.64
18.04
23.08
6/832
25/3766
8/444
13/563
1
1.00 (0.41–2.43)
2.69 (0.93–7.75)
3.43 (1.30–9.02)
0.002
Household size
(number of people)
,10
10–14
15–19
$ 20
461 (17)
700 (26)
568 (21)
950 (35)
9.02
5.39
16.83
8.02
9/998
8/1484
19/1129
16/1995
1
0.59 (0.23–1.52)
1.75 (0.79–3.86)
0.86 (0.38–1.95)
0.04
Previous TB4 No
Yes
2604 (97)
74 (3)
7.50
74.47
41/5464
11/140
1
10.14 (5.21–19.74)
,0.0001
Smoking (adults only;
age.15 yrs, n = 1647)
No
Yes
1495 (91)
152 (9)
12.26
27.64
38/3099
8/289
1
2.15 (1.00–4.60) 0.07
BCG vaccination5 No
Yes
1182 (44)
1482 (56)
9.37
9.29
23/2455
29/3120
1
1.00 (0.58–1.73)
0.99
Findings at TB diagnosis of index cases:
Cavitation on CXR6 0
1–2
3–8
372 (15)
1277 (53)
760 (31)
11.22
7.74
9.94
9/802
21/2713
15/1509
1
0.67 (0.31–1.48)
0.83 (0.36–1.89)
0.61
Number of zones on CXR 7 0–3
4–5
6
1856 (72)
616 (24)
92 (3)
8.96
9.22
15.81
35/3907
12/1301
3/190
1
1.03 (0.54–1.99)
1.72 (0.53–5.60)
0.70
Cough duration of
index case8 (weeks)
#2
3–4
5–8
.8
230 (9)
1022 (38)
662 (25)
760 (28)
8.85
5.85
11.81
11.50
4/452
13/2223
16/1355
18/1565
0.72 (0.23–2.20)
1.38 (0.46–4.13)
1.34 (0.46–3.97)
0.24
1n = 221 missing;
2based on n = 952;
3n = 14 missing;
4n = 1 missing;
5n = 15 missing;
6n = 270 missing;
7n = 115 missing (from 8 households);
8n = 5 missing (from 1 household); pyrs = person years; HR =hazard ratio; CI = confidence interval; CXR = chest radiograph; col = column; nmax=maximum number.
doi:10.1371/journal.pone.0010508.t003
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response and the risk of development of TB within two years
follow-up. Remarkably, when restricting to definite TB cases only,
the potential prognostic effect of a positive ELISPOT response
appeared quite strong, with a nearly four-fold increased risk of
active TB amongst household contacts.
A major limitation of our study was, however, the inability to
ensure Isoniazid Preventive Therapy (IPT) for all child contacts#5
years of age. As is the case with most low income countries, IPT is
underused in Senegal. For example, WHO data [16] indicate that,
in 2008, no HIV-infected patients had started IPT in Senegal, and
the Senegal National TB Control Programme report states that, in
2008, only 1476 children in the whole country received IPT, for a
detection of 11591 new smear positive TB cases. This reflects the
limited use of IPT in the country, and dialogue has been initiated
with the National TB Control Programme to stress the importance
of following international guidelines. We hope our study will
provide evidence to improve the existing situation and encourage
wider use of IPT in child contacts of infectious TB cases.
Few prospective studies have been conducted so far to
investigate the use of IGRAs as a marker of development of TB
disease given infection [8]. Our estimates of the hazard ratio for
time to TB episode incidence for TST or EC ELISPOT status at
baseline are consistent with those observed in a cohort study
conducted in a neighbouring country, The Gambia, in which the
adjusted hazard ratio of developing TB in contacts was 1.8 (0.8–
4.1) with the TST and 1.8 (0.8–4.2) with a similar in-house
ELISPOT assay using similar threshold [13]. In a cohort of child
contacts of infectious TB cases in Turkey, a positive response using
commercial IGRA (T-SPOT.TB, Oxford Immunotec, Oxford,
UK) was associated with a three-fold increase of risk of TB within
two years follow-up [17], although the risk estimates were only
adjusted on INH prophylaxis. Of note, the point estimates of risks
were similar for TST and IGRA responses. Lastly, in a study in
Germany using another commercial IGRA (QuantiFERON-TB
Gold In-Tube, Cellestis, Carnegie, Victoria, Australia), the risk of
Table 4. Univariable analysis of time to TB episode; hazard ratios, 95% CI and P-values (nmax = 2679) - Definite TB cases only
(n = 40).
Variable Description n (col %) Rate/1000 pyrs TB cases/pyrs
Unadjusted HR
(95% CI) P-value
TST response1 (mm) ,10
$ 10
867 (35)
1591 (65)
3.26
9.00
6/1840
30/3332
1
2.73 (1.14–6.56)
0.013
TST response 1 (mm) ,5
5–9.9
10–14.9
$ 15
548 (22)
319 (13)
688 (28)
903 (37)
2.51
4.65
2.77
13.76
3/1951
3/645
4/1443
26/1889
1
1.73 (0.35–8.57)
1.06 (0.24–4.73)
5.31 (1.61–17.53)
0.0002
EC response2
(SFC/Million PBMC)
,20
$ 20
337 (35)
615 (65)
4.11
11.30
3/730
15/1327
1
2.75 (0.80–9.50)
0.076
EC response2
(SFC/Million PBMC)
,32
$ 32
408 (43)
544 (58)
3.43
12.68
3/875
15/1183
1
3.76 (1.09–13.00)
0.017
Gender Male
Female
1420 (53)
1259 (47)
6.84
7.39
18/2630
22/2977
1
1.08 (0.58–2.01)
0.81
Age (years) #15
16–29
$ 30
1031 (38)
897 (33)
751 (28)
1.80
12.02
8.97
4/2216
22/1830
141560
1
6.46 (2.23–18.76)
4.86 (1.60–14.76)
0.0001
Proximity to index case at
night2
Other house
Same house
Same room
Same bed
430 (16)
1764 (66)
213 (8)
271 (10)
4.81
5.04
11.2
21.30
4/831
19/3766
5/444
12/563
1
1.15 (0.39–3.39)
2.54 (0.68–9.47)
4.80 (1.54–14.88)
0.0001
1n = 221 missing;
2based on n = 952; pyrs = person years; HR = hazard ratio; CI = confidence interval; CXR = chest radiograph; col = column; nmax=maximum number.
doi:10.1371/journal.pone.0010508.t004
Table 5. Multivariable analysis of time to TB episode (all TB
cases and definite TB cases only); unadjusted and adjusted
hazard ratios, 95% CI and P-values, separately for TST and EC
responses.
Variable n
Unadjusted
HR
Adjusted HR1
(95% CI) P-value
All TB cases (n = 52)
TST response
(mm)
,10
$ 10
2458 1
2.37
1
1.55 (0.74–3.24)
0.23
TST response
(mm)
,5
5–9
10–14
$ 15
2458 1
2.18
1.40
4.92
1
1.27 (0.34–4.82)
0.73 (0.21–2.56)
2.56 (0.88–7.41)
0.005
EC response
(SFC/million
PBMC)
,32
$ 32
951 1
2.13
1
1.98 (0.77–5.08)
0.14
Definite TB cases (n = 40)
TST response
(mm)
,10
$ 10
2458 1
2.73
1
1.73 (0.71–4.23)
0.20
TST response
(mm)
,5
5–9
10–14
$ 15
2458 1
1.73
1.06
5.31
1
0.94 (0.19–4.72)
0.52 (0.11–2.36)
2.58 (0.76–8.74)
0.003
EC response
(SFC/million
PBMC)
,32
$ 32
951 1
3.77
1
3.61 (1.03–12.65)
0.02
1adjusted for sex, age group, proximity to index case.
HR = hazard ratio; CI = confidence interval.
doi:10.1371/journal.pone.0010508.t005
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developing TB was better predicted by a positive IGRA response
in contacts who had a positive TST response (.5 mm), but this
effect disappeared if the 10 mm threshold was used [18]. In all
these studies, the risk of development of TB according to IGRA
response was not adjusted on age, sex and proximity to TB cases.
In this, our estimates can be considered more robust, and less
liable to bias due to confounding factors.
Individuals with both TST and EC positive responses had a
slightly higher incidence rate of TB (14.74/1000 pyrs) than
individuals positive with either test alone (11.15/1000 pyrs),
although 95%CI overlap. The high rate of TB in individuals with
concordant negative TST and EC responses could be driven by
concurrent HIV infection [19] that may affect the performance of
the ELISPOT [12]. Individuals with discordant responses had the
lowest rates of TB. In subjects with TST+/ELISPOT- responses,
this could be due to a false positive TST, reflecting former
sensitization by either BCG or environmental mycobacteria. This
could also indicate a genuine difference between TST and IGRA
in their ability to detect remote - and probably cleared - infection
vs. recent, persisting TB infection [20]. The reason for TST-/
ELISPOT+ response discordance is unclear, but could be related
to variations around the respective thresholds, since both tests are
continuous measures [20,21].
The validation of IGRAs to detect LTBI suffers from the lack of
gold standard, so active TB disease has often been used as a proxy
marker for LTBI [4]. Using this approach, IGRAs have been
shown to be as sensitive as, and more specific than, TST for
detecting LTBI [5,9]. Given this, it may be surprising that in our
study a combination of both positive TST and positive ELISPOT
appears just slightly better at predicting TB than a positive TST or
a positive ELISPOT response alone, and that subjects with
discordant responses to both tests had the lowest rate of developing
TB. This could be understood if we consider that the detection of
an adaptative immune response towards mycobacterial antigens is
only a footprint of a former contact of the immune system with these
organisms, which may not necessarily reflect the presence of living
mycobacteria [21]. In this respect, TST and ELISPOT are
probably not equivalent in what they measure. It has recently been
suggested that T-cells responding to the RD antigens after 24 h
stimulation are predominantly CD4 T-cells of an effector memory
phenotype, consistent with having recently encountered antigens in
vivo, while TST reflects the mobilization of a wider spectrum of
memory T-cells that are long-lived and may even persist after
clearance of live mycobacteria [21]. Recent data suggest that
IGRA responses amongst contacts of TB cases are highly variable
over time, and that a continued exposure to M.tuberculosis is
necessary to maintain a high IGRA response [22,23]. It has been
hypothesized that, as individuals who have been recently exposed to
TB offer a vigorous T-cell response to active bacterial replication
Figure 2. Box plots of EC ELISPOT response (SFC/million PBMC) at baseline by TB status in follow-up.
doi:10.1371/journal.pone.0010508.g002
Table 6. Incidence rates by TST and EC response (restricted
to those with both TST and EC response data, n = 893).
Description
n
(col %)
TB cases/
pyrs
Rate per
1000 pyrs 95% CI
TST ,10 and EC,32
TST $10 and EC,32
TST ,10 and EC$32
TST $10 and EC$32
187 (21)
193 (22)
77 (9)
436 (49)
4/406
2/406
1/170
14/950
9.85
4.93
5.90
14.74
3.79 – 26.25
1.23 – 19.70
0.83 – 41.87
8.73 – 24.89
TST$10 or EC$32 706 (79) 17/152 11.15 6.93 – 17.93
TST ,10
TST $10
264 (30)
629 (70)
5/576
16/1356
8.69
11.80
3.62 – 20.87
7.23 – 19.27
EC,32
EC$32
380 (43)
513 (57)
6/811
15/1119
7.39
13.40
3.32 – 16.45
8.08 – 22.23
CI = confidence interval; pyrs = person years.
doi:10.1371/journal.pone.0010508.t006
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[24], strong increases in IGRA response after recent exposure
might predict progression to active disease [8,25]. Our findings
support this hypothesis, since the magnitude of the ELISPOT
response was 5-fold higher in contacts who developed TB
compared to those who did not develop TB, and the significant
difference in performance of the ELISPOT compared to the TST
was only seen in definite TB cases. This is in line with recent
findings of a similar study in Columbia, a country of medium TB
prevalence, where the rate of development of TB was highest in
household contacts with high IFN-c response to CFP-10 at
baseline [26].
Current cut-off values for commercially available IGRA assays
are set at relatively low levels in order to maximize the detection of
individuals with M. tuberculosis infection who might benefit from
chemoprophylaxis, especially amongst contacts of TB cases
[27,28]. In a setting where TB is endemic and households are
large and likely to contain co-prevalent TB cases, it would be
extremely difficult to determine the exact time of TB exposure
(where an IGRA assay is likely to perform the best). In this
situation there may be bias towards the longer lived TST response
which outweighs the benefit of the increased specificity of the more
transient IGRA response. Our findings indicate that a combina-
tion of the TST and ELISPOT might be best predictive of TB
infection in household contacts of TB patients, and that the level of
IFN-c response to specific M.tuberculosis antigens may have
prognostic value for the development of TB disease in this high-
risk group [25,26]. They confirm the need for extensive
investigations of contacts of infectious TB cases when diagnosed,
so as to identify individuals who may best benefit from
chemoprophylaxis [29,30] This should be conducted within the
context of a full risk assessment that takes into consideration both
individual characteristics and the intensity of exposure. However,
given the highly dynamic nature of the IGRA response over time
[23,31], that probably reflects the variety of the underlying latent
TB infection phenotypes [32], further prospective studies are
needed to monitor conversion and reversion of IGRAs amongst
contacts of infectious TB cases and their association with later
development of TB. This would help defining a commonly
acceptable threshold for definition of LTBI and the determination
of a second cut-off that could be used to identify those most at risk
of development of TB, who may therefore benefit most from
preventive therapy.
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